163 related articles for article (PubMed ID: 1760884)
1. Phosphatase isoenzymes as bone metastasis markers in prostatic carcinoma.
Desoize B; Amico S; Larbre H; Coninx P; Jardillier JC
Clin Biochem; 1991 Oct; 24(5):443-6. PubMed ID: 1760884
[TBL] [Abstract][Full Text] [Related]
2. Comparison of phosphatase isoenzymes PAP and PSA with bone scan in patients with prostate carcinoma.
Amico S; Liehn JC; Desoize B; Larbre H; Deltour G; Valeyre J
Clin Nucl Med; 1991 Sep; 16(9):643-8. PubMed ID: 1718651
[TBL] [Abstract][Full Text] [Related]
3. Prediction of bone metastases by combination of tartrate-resistant acid phosphatase, alkaline phosphatase and prostate specific antigen in patients with prostate cancer.
Ozu C; Nakashima J; Horiguchi Y; Oya M; Ohigashi T; Murai M
Int J Urol; 2008 May; 15(5):419-22. PubMed ID: 18452459
[TBL] [Abstract][Full Text] [Related]
4. [Evaluation of two serum isoenzyme phosphatases as bone metastasis markers].
Desoize B; Pourny C; Amico S; Larbre H; Jardillier JC
Bull Cancer; 1990; 77(12):1211-21. PubMed ID: 2081281
[TBL] [Abstract][Full Text] [Related]
5. Relationship between prostate-specific antigen, clinical stage, and degree of bone metastasis in patients with prostate cancer: comparison with prostatic acid phosphatase and alkaline phosphatase.
Akimoto S; Furuya Y; Akakura K; Shimazaki J; Ito H
Int J Urol; 1997 Nov; 4(6):572-5. PubMed ID: 9477186
[TBL] [Abstract][Full Text] [Related]
6. Isoenzymes of alkaline and acid phosphatases as bones metastasis marker in breast cancer patients.
Desoize B; Veiler V; Pourny C; Comoe L; Jardillier JC
Anticancer Res; 1989; 9(4):1105-9. PubMed ID: 2817792
[TBL] [Abstract][Full Text] [Related]
7. Serum tartrate-resistant acid phosphatase 5b (TRACP 5b) as a marker of skeletal changes in prostate cancer.
Salminen E; Ala-Houhala M; Korpela J; Varpula M; Tiitinen SL; Halleen JM; Väänänen HK
Acta Oncol; 2005; 44(7):742-7. PubMed ID: 16227166
[TBL] [Abstract][Full Text] [Related]
8. Plasma acid and alkaline phosphatase in patients with breast cancer.
Nguyen M; Bonneterre J; Hecquet B; Desoize B; Demaille A
Anticancer Res; 1991; 11(2):831-3. PubMed ID: 2064338
[TBL] [Abstract][Full Text] [Related]
9. Implications of serum bone turnover markers in prostate cancer patients with bone metastasis.
Kamiya N; Suzuki H; Yano M; Endo T; Takano M; Komaru A; Kawamura K; Sekita N; Imamoto T; Ichikawa T
Urology; 2010 Jun; 75(6):1446-51. PubMed ID: 20206975
[TBL] [Abstract][Full Text] [Related]
10. The significance of serum alkaline phosphatase bone isoenzyme in prostatic carcinoma with bony metastasis.
Chen SS; Chen KK; Lin AT; Chang YH; Wu HH; Hsu TH; Chang LS
Br J Urol; 1997 Feb; 79(2):217-20. PubMed ID: 9052473
[TBL] [Abstract][Full Text] [Related]
11. Survival markers related to bone metastases in prostate cancer.
Salminen EK; Kallioinen MJ; Ala-Houhala MA; Vihinen PP; Tiitinen SL; Varpula M; Vahlberg TJ
Anticancer Res; 2006; 26(6C):4879-84. PubMed ID: 17214355
[TBL] [Abstract][Full Text] [Related]
12. The use of serum isoenzymes of alkaline and acid phosphatase as possible quantitative markers of tumor load in prostate cancer.
Killian CS; Vargas FP; Pontes EJ; Beckley S; Slack NH; Murphy GP; Chu TM
Prostate; 1981; 2(2):187-206. PubMed ID: 7301655
[TBL] [Abstract][Full Text] [Related]
13. Bone scintigraphy and serum phosphatases in the detection and follow-up of bone metastases in prostatic cancer.
Liewendahl K; Alfthan O; Ikonen T; Ruutu M; Rannikko S
Scand J Urol Nephrol; 1984; 18(3):181-5. PubMed ID: 6494827
[TBL] [Abstract][Full Text] [Related]
14. Serum tartrate resistant acid phosphatase as a potential marker of bone metastasis from breast cancer.
Wada N; Ishii S; Ikeda T; Enomoto K; Kitajima M
Anticancer Res; 1999; 19(5C):4515-21. PubMed ID: 10650803
[TBL] [Abstract][Full Text] [Related]
15. [Measurement of skeletal alkaline phosphatase in prostatic carcinoma. Preliminary report].
Casetta G; Gamba P; Piana P; Pecchio F; Tizzani A
Minerva Urol Nefrol; 1995 Mar; 47(1):9-12. PubMed ID: 7570264
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of serum BAP, TRACP 5b and ICTP as bone metabolic markers for bone metastasis screening in lung cancer patients.
Tang C; Liu Y; Qin H; Li X; Guo W; Li J; Wang W; Qu L; Hu H; Xu C; Zheng L; Huang Y; Liu B; Gao H; Halleen JM; Liu X
Clin Chim Acta; 2013 Nov; 426():102-7. PubMed ID: 24055775
[TBL] [Abstract][Full Text] [Related]
17. Advanced prostate cancer follow-up with prostate-specific antigen, prostatic acid phosphatase, osteocalcin and bone isoenzyme of alkaline phosphatase.
Curatolo C; Ludovico GM; Correale M; Pagliarulo A; Abbate I; Cirrillo Marucco E; Barletta A
Eur Urol; 1992; 21 Suppl 1():105-7. PubMed ID: 1385127
[TBL] [Abstract][Full Text] [Related]
18. [Relationship of serum prostate-specific antigen and alkaline phosphatase levels with bone metastases in patients with prostate cancer].
Wang ZL; Wang XF
Zhonghua Nan Ke Xue; 2005 Nov; 11(11):825-7. PubMed ID: 16333960
[TBL] [Abstract][Full Text] [Related]
19. Tartrate-resistant acid phosphatase 5b activity is a useful bone marker for monitoring bone metastases in breast cancer patients after treatment.
Chung YC; Ku CH; Chao TY; Yu JC; Chen MM; Lee SH
Cancer Epidemiol Biomarkers Prev; 2006 Mar; 15(3):424-8. PubMed ID: 16537696
[TBL] [Abstract][Full Text] [Related]
20. Comparison of markers of bone formation and resorption in prostate cancer patients to predict bone metastasis.
Akimoto S; Furuya Y; Akakura K; Ito H
Endocr J; 1998 Feb; 45(1):97-104. PubMed ID: 9625452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]